ZUMA-3: Brexu-cel continues to provide OS benefit at more than four years of follow-up in patients with R/R B-ALL

ASH 2025

Lymphoma

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

ASH 2025

Multiple Myeloma (MM)

KarMMa-3: Ide-cel demonstrates clinical benefit in patients aged 70 years and older with RRMM

CHICAGO 2026

Breast Cancer

KEYNOTE-522: Pembrolizumab plus chemotherapy provides sustained EFS and OS benefits at 8-year follow-up in high-risk early-stage TNBC

WCLC 2025

Lung, Respiratory and Thoracic Cancer

EMPOWER-Lung 3: Cemiplimab plus chemotherapy provide sustained survival benefits in patients with advanced NSCLC

Multiple Myeloma (MM)

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM

WCLC 2025

Lung, Respiratory and Thoracic Cancer

CheckMate 816: Neoadjuvant nivolumab plus chemotherapy provides long-term OS benefit in patients with early-stage NSCLC

CHICAGO 2026

Lymphoma

Real-world analysis demonstrates sustained responses with axi-cel in patients with R/R LBCL

Breast Cancer

Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up

J Natl Cancer Inst

Danielsson O, Dar H, Nordenskjöld A, Perez-Tenorio G, Nordenskjöld B, Fornander T, Stål O, Tobin NP, Tutzauer J, Johansson A, Lindström LS

doi: 10.1093/jnci/djag049

Lymphoma

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study

J Clin Oncol

Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Chow VA, Montheard S, Santamaria J, Colicino S, Ogasawara K, Stepan L, Liu FF, Abramson JS

doi: 10.1200/JCO-25-00399

Related content

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

KarMMa-3: Ide-cel demonstrates clinical benefit in patients aged 70 years and older with RRMM

KEYNOTE-522: Pembrolizumab plus chemotherapy provides sustained EFS and OS benefits at 8-year follow-up in high-risk early-stage TNBC

EMPOWER-Lung 3: Cemiplimab plus chemotherapy provide sustained survival benefits in patients with advanced NSCLC

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

CheckMate 816: Neoadjuvant nivolumab plus chemotherapy provides long-term OS benefit in patients with early-stage NSCLC

Real-world analysis demonstrates sustained responses with axi-cel in patients with R/R LBCL

Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM